(653) Rapid Change in Microbiome Profiles Regardless of Diagnostic Method in a Post Hoc Comparative Analysis of Phase 3 Trials of Fecal Microbiota Spores, Live-brpk (formerly SER-109) for the Prevention of Recurrent Clostridioides difficile Infection (rCDI)

Assistant Professor
Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy
Houston, TX, United States

Director
Seres Therapeutics, Inc.
Cambridge, MA, United States

Seres Therapeutics, Cambridge, MA
Cambridge, Massachusetts, United States

Aimmune Therapeutics, a Nestlé Health Science company, Brisbane, CA
Brisbane, California, United States

Vice President
Seres Therapeutics, Inc.
Cambridge, MA, United States

Seres Therapeutics, Cambridge, MA
Cambridge, Massachusetts, United States

Director of Infectious Diseases Research
Beaumont Health
Royal Oak, Michigan, United States

Vice President
Seres Therapeutics, Inc
Cambridge, Massachusetts, United States

EVP, Chief Scientific Officer
Seres Therapeutics, Cambridge, MA
Cambridge, Massachusetts, United States